Abiomed's Minogue pushes House committee on device tax repeal

The Supreme Court of the United States may have upheld the national health reform law, and, by default, the 2.3% medical device excise tax that will help support it. But the industry's battle to overturn the assessment marches on. This time, industry group AdvaMed enlisted Abiomed ($ABMD) Chairman, President and CEO Michael Minogue to testify before the House Committee on Small Business about the tax and the need to repeal it. He told committee members that two-thirds of the 7,000 medical device companies in the U.S. employ fewer than 20 people, with many breakthrough devices and diagnostics coming "from small, often venture capital-funded companies." The tax, if allowed to kick in as planned on Jan. 1, will damage these younger companies because they lose money for years as they try to move a product to market, Minogue explained. "This tax increases the time these struggling companies will be operating at a loss," he noted. "For some, it could truly be the difference between surviving and having to close their doors." Release

Suggested Articles

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.

CMR Surgical will have a new CEO at the top of the year, as it kicks off the global launch of its modular Versius system while awaiting FDA approval.

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.